Unlike other breast cancer subtypes, triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), making it unresponsive to hormonal and HER2-targeted therapies [6,7,8]. Here, ESR1 is linked to triple-negative breast carcinoma.